Pilot Study: Effects of Nimodipine on Alcohol Drinking

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06900998
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Nimodipine — DRUG
    Nimodipine will be administered orally beginning on the evening prior to the study lab session. 90mg doses will be administered at 6:00pm, 12:00am, 6:00am, and 12:00pm.

Study Details

This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).

Key Dates

Start date
Sep 1, 2026
Status verified
Oct 2025
Primary completion
Jun 30, 2032
Completion
Jun 30, 2032

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Nimodipine
    All participants will be assigned to this arm and will receive study drug (nimodipine), open label.

Primary Outcome Measure

Number of drinks consumed [ Time Frame: Lab Session 1 (Day 1) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale University School of Medicine (Connecticut Mental Health Center)New HavenConnecticut06519
Thomas Liss
[email protected]
2034447545
Suchitra Krishnan-Sarin, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
Yale University School of Medicine (Connecticut Mental Health Center)· New Haven, CT

Related Studies